

Making PBPK models more reproducible in practice

Downloaded from: https://research.chalmers.se, 2024-11-21 19:29 UTC

Citation for the original published paper (version of record):

Domínguez-Romero, E., Mazurenko, S., Scheringer, M. et al (2024). Making PBPK models more reproducible in practice. Briefings in Bioinformatics, 25(6). http://dx.doi.org/10.1093/bib/bbae569

N.B. When citing this work, cite the original published paper.

research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology. It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004. research.chalmers.se is administrated and maintained by Chalmers Library

https://doi.org/10.1093/bib/bbae569 Review

Making PBPK models more reproducible in practice

Elena Domínguez-Romero $\blacksquare^{1,2,*}$ $\blacksquare^{1,2,*}$ $\blacksquare^{1,2,*}$, Stanislav Mazurenko $\blacksquare^{3,4}$ $\blacksquare^{3,4}$ $\blacksquare^{3,4}$ $\blacksquare^{3,4}$, Martin Scheringer \blacksquare^2 , Vítor A.P. Martins dos Santos \blacksquare^5 \blacksquare^5 , Chris T. Evelo \mathbb{D}^1 \mathbb{D}^1 , Mihail Anton $\mathbb{D}^{6,7,\ddagger}$ $\mathbb{D}^{6,7,\ddagger}$ $\mathbb{D}^{6,7,\ddagger}$ $\mathbb{D}^{6,7,\ddagger}$ $\mathbb{D}^{6,7,\ddagger}$, John M. Hancock $\mathbb{D}^{8,\ddagger}$ $\mathbb{D}^{8,\ddagger}$ $\mathbb{D}^{8,\ddagger}$, Anže Županič $\mathbb{D}^{9,\ddagger}$ $\mathbb{D}^{9,\ddagger}$ $\mathbb{D}^{9,\ddagger}$, Maria Suarez-Diez $\mathbb{D}^{10,\ddagger}$ $\mathbb{D}^{10,\ddagger}$ $\mathbb{D}^{10,\ddagger}$

[1](#page-1-11)Department of Bioinformatics—BiGCaT, School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands

[2](#page-1-12)RECETOX, Faculty of Science, Masaryk University, Kotlarska 2, 611 37, Brno, Czech Republic

[3](#page-1-13)Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic [4](#page-1-14)International Clinical Research Center, St. Anne's University Hospital Brno, Pekarská 53, 656 91, Brno, Czech Republic ˇ

[5](#page-1-15)Laboratory of Bioprocess Engineering, Wageningen University and Research, Droevendaalsesteeg 1, 6708 PB, Wageningen, The Netherlands

[6](#page-1-16)ELIXIR, Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, United Kingdom

[7](#page-1-17)Department of Life Sciences, National Bioinformatics Infrastructure Sweden (NBIS), SciLifeLab, Chalmers University of Technology, Kemigården 1, Gothenburg SE-412 96, Sweden

[8](#page-1-18)Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia

[9](#page-1-19)Department of Biotechnology and Systems Biology, National Institute of Biology, Večna pot 121, 1000 Ljubljana, Slovenia

[10](#page-1-20)Laboratory of Systems and Synthetic Biology (SSB), Wageningen University and Research, Agrotechnology and Food Sciences, Stippeneng 4, 6708 WE Wageningen, The Netherlands

[*](#page-1-21)Corresponding author. Department of Bioinformatics—BiGCaT, Maastricht University, Maastricht, The Netherlands.

E-mail: [elena.dominguez-romero@maastrichtuniversity.nl](
16 26461 a 16 26461 a
)

 \dagger Mihail Anton, John M. Hancock, Anže Županič and Maria Suarez-Diez are the last authors for this work.

Abstract

Systems biology aims to understand living organisms through mathematically modeling their behaviors at different organizational levels, ranging from molecules to populations. Modeling involves several steps, from determining the model purpose to developing the mathematical model, implementing it computationally, simulating the model's behavior, evaluating, and refining the model. Importantly, model simulation results must be reproducible, ensuring that other researchers can obtain the same results after writing the code *de novo* and/or using different software tools. Guidelines to increase model reproducibility have been published. However, reproducibility remains a major challenge in this field. In this paper, we tackle this challenge for physiologically-based pharmacokinetic (PBPK) models, which represent the pharmacokinetics of chemicals following exposure in humans or animals. We summarize recommendations for PBPK model reporting that should apply during model development and implementation, in order to ensure model reproducibility and comprehensibility. We make a proposal aiming to harmonize abbreviations used in PBPK models. To illustrate these recommendations, we present an original and reproducible PBPK model code in MATLAB, alongside an example of MATLAB code converted to Systems Biology Markup Language format using MOCCASIN. As directions for future improvement, more tools to convert computational PBPK models from different software platforms into standard formats would increase the interoperability of these models. The application of other systems biology standards to PBPK models is encouraged. This work is the result of an interdisciplinary collaboration involving the ELIXIR systems biology community. More interdisciplinary collaborations like this would facilitate further harmonization and application of good modeling practices in different systems biology fields.

Keywords: systems biology; pharmacokinetics; model code; reproducibility; SBML; MATLAB

Introduction

Systems biology is a scientific field that aims to understand living organisms as whole systems, by modeling them at different organizational levels [[1,](#page-11-0) [2](#page-11-1)]. Key challenges in systems biology include the resistance to mathematical modeling in biological sciences and the need to improve the comprehensiveness, 'reproducibility', and 'interoperability' of systems biology models [[3–](#page-11-2)[6](#page-11-3)], data integration and multi-scale modeling [[7](#page-11-4), [8](#page-11-5)]. 'Reproducibility', 'interoperability', and other important terms are explained in [Table 1](#page-2-0).

A systems biology model is a simplified representation of a biological system. The biological levels that may be represented range from molecules, cells, tissues and organs, to whole

organisms and populations [[2\]](#page-11-1). In this paper, we focus on a type of systems biology model that is of particular importance for the pharmacology and toxicology communities, physiologicallybased pharmacokinetic (PBPK) models. PBPK models are one type of mechanistic quantitative systems pharmacology (QSP) models [[7](#page-11-4)]. PBPK models represent the processes of absorption, distribution, metabolism, and elimination of chemicals—abbreviated as 'ADME', also known as pharmacokinetics, following exposure in humans or animal species [\[9](#page-11-6)]. These models allow linking the external exposure to a chemical with its absorption in the organism and the resulting internal exposure levels, represented by the time-dependent concentrations of the chemical—and/or its derived metabolites—in organs and tissues. PBPK models use

Received: July 11, 2024. **Revised:** September 28, 2024. **Accepted:** October 22, 2024 © The Author(s) 2024. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

aOne of the denominated 'FAIR principles'. Briefly: 'all research objects should be findable, accessible, interoperable, and reusable (FAIR) both for machines and for people' (Wilkinson *et al.*, 2016; Jacobsen *et al.*, 2020). In this Table, we provide our interpretation of these principles as applied for systems biology models. ^bIn a broader research context, the term 'reproducibility' can be divided into: 'methods reproducibility': the methods should be sufficiently detailed to allow an exact repetition of procedures by others; 'results reproducibility': the ability for an independent study to obtain the same results, which requires methods reproducibility too; 'inferential reproducibility': the ability for an independent study to reach the same conclusions after either replicating or reanalyzing the original study [[19](#page-12-4), [23\]](#page-12-9).

ordinary differential equations (ODE) and include a realistic representation of relevant anatomical and physiological traits in the organism. They also take into account the biochemical characteristics of a substance (or chemical group) that impact its pharmacokinetics, and consider one or more external exposure scenarios [[22,](#page-12-8) [24](#page-12-10)]. PBPK models are major tools in toxicological risk assessment of chemicals, where they can be combined with other types of models and data, and used for several regulatory applications [\[9,](#page-11-6) [22](#page-12-8), [25](#page-12-11)[–27\]](#page-12-12).

The typical process of PBPK modeling is iterative and organized in several steps. The first step focuses on determining a clear purpose to develop a model, such as a precise scientific or regulatory question concerning an organism of interest. The second step is conducting a literature search, to have a global understanding of this organism and the chemical group of interest, and to identify the main exposure routes, processes, and interactions to consider for the research question. This information allows the creation of a 'conceptual model', which is a graphical overview of the

processes to be represented. This stage also involves defining hypotheses about the system of interest. Importantly, to be able to simulate the model and make quantitative estimations, the conceptual model must further be developed by creating a 'mathematical model' and a 'computational model', the latter also often referred to as the 'model code' (see definitions in [Table 1\)](#page-2-0). The third step is then the definition of the mathematical model, which specifies the mathematical equations, conditions (in this case, exposure scenarios) and the data used for model development and validation [\[12,](#page-11-9) [13](#page-11-10)]. This step often involves mining literature and/or databases to find (and evaluate) available parameter values. The fourth step is coding the model by using numeric algorithms, a specific solver and numeric tools [\(Table 1\)](#page-2-0). This way, the model is implemented in a machine-readable (programming) language. Upon code execution, the model solver performs a numerical integration to simulate the model's behavior in time (and/or space), under predetermined simulation conditions [[9](#page-11-6), [10,](#page-11-7) [12,](#page-11-9) [13](#page-11-10), [20\]](#page-12-6). Further steps include model evaluation through sensitivity analysis and model validation. Often an iterative approach is used to progressively refine the model to align with experimental observations and if needed update model parameters.

Computational studies must be 'repeatable', allowing other researchers to repeat the study by using the same source code and data [[17](#page-12-3)], and 'reproducible', allowing other researchers to reproduce the model results after rebuilding the model or applying it using different software (see [Table 1](#page-2-0)). This enables model peerreview and reuse.

To facilitate model reproducibility, good practices for encoding, annotating and describing a mathematical biological model exist in the literature. For example, Le Novere *et al.* [[10\]](#page-11-7) proposed the 'Minimum information requested in the annotation of biochemical models (MIRIAM*)*' standard. Globally, the MIRIAM recommendations highlighted the need for consistency between the model code and a single reference description of the mathematical model. MIRIAM specified the main information to include in the model description (equations, parameter values, initial condition values, simulation results), and annotation (model authors, model version and others). The MIRIAM guidelines were extended by the 'Minimum Information About a Simulation Experiment (MIASE)' guidelines [[20\]](#page-12-6). Besides compliance with MIRIAM, MIASE requires a full description of the simulation conditions applied to obtain the model quantitative results, including the software used and information on any possible modification of parameter values before simulation.

In addition to the MIRIAM and MIASE guidelines for model documentation, specific good modeling practices for PBPK models also exist [[22,](#page-12-8) [28\]](#page-12-13). Andersen *et al.* [\[22\]](#page-12-8) highlighted the need to explain the model purpose and the hypothesis tested, present all the equations, values and units of parameters and variables (as in MIRIAM), state the model validity domain (e.g. species, age, physiological stage, chemical group), define the criteria applied for model evaluation (such as sensitivity and uncertainty analyses), describe the software used (as in MIASE) and make the code available upon request. Loizou *et al.* [\[28](#page-12-13)] mentioned the benefit for PBPK models of using standard encoding languages such as Systems Biology Markup Language (SBML) or CellML. Additionally, there are guidelines for documentation and evaluation of PBPK models developed for risk assessment purposes [\[9](#page-11-6), [29](#page-12-14)].

In spite of existing guidance, the reproducibility of systems biology models is still a challenge. As an illustration, Tiwari *et al.* [[18](#page-12-5)] analysed the reproducibility of 455 published deterministic ODE models, previously submitted to the BioModels repository [[14](#page-12-0)]. Among these models, 49% were not directly reproducible, of which only approximately one quarter (12% of all models included in that study) were reproducible after manual correction, and three quarters (37% of the total) were not reproducible in any manner. More emphatically, Porubsky *et al.* [\[17\]](#page-12-3) cited two independent studies by the BioModels and the Physiome repository groups, where the reproducibility of *>*1200 systems biology and physiology models was assessed. In those studies, *>*95% of the models evaluated were not reproducible (personal communication quoted by Porubsky *et al.* [[17\]](#page-12-3)). Tiwari *et al.* [[18\]](#page-12-5) identified several causes that limited model reproducibility, notably errors in the parameters and the initial conditions (missing values, incorrect units) and inconsistency of the model structure (errors in equations, missing terms, incorrect signs). In this context, to help estimate the reproducibility of systems biology models, Tiwari *et al.* [\[18\]](#page-12-5) proposed a reproducibility scorecard, which focused on the most important information needed to ensure the model reproducibility, in line with MIRIAM and MIASE guidelines. Concerning the model code, the reproducibility scorecard pointed to the need for clarity, the importance of including a set of numerical results, the preference for using standard languages such as SBML and publishing the model in public repositories.

The low reproducibility of ODE-based biological models as reported by Tiwari *et al.* [\[18](#page-12-5)] may be an issue for PBPK models too. For example, Thompson *et al.* [\[30\]](#page-12-15) reviewed 7541 PBPK models. As part of their review, the authors created and published a database containing the main descriptors (metadata) per model [[31\]](#page-12-16).Within the database created by Thompson *et al.*[[30\]](#page-12-15), we found information for 1657 literature references based on their reference name and DOI. Of these, only 508 references (31%) were annotated as showing the full model equations either in the paper or in supplementary information. By contrast, the equations were not available for 528 references (32%). The model code was directly available only in 68 references (4.1%), generally as supplementary information (3.8%), with few exceptions where the code was published in BioModels or GitHub (0.3%). Out of 69 software platforms identified in the database by Thompson *et al.* [\[30\]](#page-12-15), the preferred tools (% of all references) were: Simcyp (13.5%), ACSL (10.4%), MATLAB (7.2%), Berkeley Madonna (6.0%), and SIMUSOLV (5.4%). By contrast, the simulation software was not specified in 18% of all references. In summary, there is evidence that the reproducibility of PBPK models also needs to be improved.

In this paper, we aim to: (i) help improve PBPK model reproducibility, and (ii) increase the comprehensibility of PBPK models for colleagues working in other fields of systems biology, given that each field requires a high level of specialization, to aid better communication and collaboration with other systems modelers. As summarized in [Fig. 1](#page-4-0), we provide a summary of recommendations for PBPK model reporting and implementation, in order to ensure reproducibility. This includes a proposal towards harmonizing abbreviations for PBPK model components. Finally and importantly, to illustrate all these recommendations, we present an original, reproducible, and flexible PBPK model code example ([Fig. 1](#page-4-0)) alongside an example of the MATLAB code converted to SBML format using MOCCASIN—the conversion to SBML enables re-use of the model outside the MATLAB environment.

Materials and methods

Providing general recommendations for documentation and implementation of PBPK models

In general to ensure the reproducibility of a PBPK model, the model should be fully explained in and implemented through two

How to \uparrow the reproducibility and understandability of PBPK models in practice?

Figure 1. Graphical abstract of the research question and workflow in the current study. (a) (also shown with violet letters): information regarding notably the mathematical model description. The model diagram is shown (left), where, *A*tissue and *C*tissue represent the amount (mg) and the concentration of chemical in a tissue (mg/kg), respectively. *Dose* is the intravenous infusion of chemical (mg/min). *QC* is the cardiac output (L/min). *Q*tissue is the blood flow (L/min) to a tissue. *PC*_{tissue} is the partition coefficient (L/kg) of the chemical between a tissue and the blood. *ER*_{liver} is the extraction ratio of the chemical in the liver (unitless). (b) (also shown with green letters): information regarding the model implementation (code). A screenshot with part of the SBML code is shown (center), and the model simulation figure (right). As an example, the same exposure scenario as by Upton *et al.* [[32](#page-12-17)] was considered.

main documents, which must be consistent and cite each other [\[10](#page-11-7), [12,](#page-11-9) [13,](#page-11-10) [16](#page-12-2), [20\]](#page-12-6):

- 1) A peer-reviewed journal article or, at minimum, a single reference description, where the mathematical model [\(Table 1\)](#page-2-0) is described, and
- 2) The model code, which is the implementation of the mathematical model in software, including notably correct numeric algorithms and a specific solver, and which may require specific software libraries. The code allows model simulation in time, under specific conditions.

In order to develop and optimize both documents, we reviewed, summarized and completed recommendations for model description, documentation and annotation from major literature sources, notably:

- the MIRIAM set of rules [\[10\]](#page-11-7), and 'reproducibility scorecard' [[18](#page-12-5)];
- the MIASE guidelines [\[20\]](#page-12-6);
- the 'model reporting template' for PBPK model assessment in a regulatory context by OECD (2021) [[9](#page-11-6)] and the PBPK reporting Guidelines by the European Medicines Agency [\[33\]](#page-12-18). From these two sources, we include requirements for reporting of PBPK models in general. We do not include additional requirements for PBPK models created for specific regulatory purposes, which are explained elsewhere [\[9,](#page-11-6) [13](#page-11-10), [33](#page-12-18)].

Description of the PBPK model

We defined a simple, illustrative PBPK mathematical model for an adult man, adapted from a conceptual model by Upton *et al.* [\[32\]](#page-12-17). Similar to that model, our mathematical model contains three

compartments. These are the blood, liver, and 'others' (meaning other body organs and tissues). Following intravenous exposure to the chemical, the distribution of the chemical from blood to liver and 'others' and vice versa (from liver and 'others' to blood) as well as the elimination of the chemical in liver are represented (see [Fig. 2](#page-5-0)). As an example of an exposure scenario, we use the same dose and exposure time as in Upton *et al.* [[32](#page-12-17)]: 100 mg/min for 200 min, followed by 200 min of depuration. We consider a hypothetical hydrophobic chemical that could globally have a higher accumulation in organs/tissues with higher total fat content (a simplifying hypothesis). The exposure scenario is an example and has no meaning in terms of saturable kinetics or chemical toxicity, which are not represented in the model. Differences between the mathematical model here and the conceptual model proposed by Upton *et al.* [[32](#page-12-17)] are as follows:

- We use physiological parameter values representative for adult men ([Table 2](#page-6-0)), as an example. For information, physiological parameter values for adult women are also shown in [Table 2](#page-6-0) and within the code.
- • We represent intravenous administration of the chemical as an input into the blood compartment [\[34](#page-12-19)].
- • We use classical flow-limited distribution equations, including partition coefficients of the chemical between each tissue and the blood (*PC*_{tissue}, L/kg) [[34,](#page-12-19) [35](#page-12-20)]. Under the simplifying hypothesis of a hydrophobic chemical with a higher accumulation in organs/tissues with higher total fat content, we selected random *PC*_{tissue} values higher than 1, because the average fat contents in the whole body (21.3% of BW in men, 32.7% of BW in women) and liver (7% of liver wet weight) are higher than the lipid content in blood (0.65%) [[36](#page-12-21), [37](#page-12-22)].

Figure 2. Diagram of the conceptual PBPK mathematical model, adapted from the conceptual model by Upton *et al.* (2016), with the differences explained in the Material and methods. *A* is the amount of the chemical in a given compartment (mg). *C*blood, *C*liver, and *C*others are the concentrations of the chemical in the blood (mg/L), liver and other body tissues (mg/kg), respectively. *Dose* is the intravenous infusion of the drug (mg/min). *QC* is the cardiac output (L/min). Q_{others} and Q_{liver_total} are the blood flows (L/min) to other body tissues and to the liver, respectively. *PC*_{others} and *PC*_{liver} are the partition coefficients (L/kg) of the chemical in other body tissues and the liver, respectively. *ER*liver is the extraction ratio of the chemical in the liver (unitless). The parameter values are shown in [Tables 2](#page-6-0) and [3.](#page-7-0)

• The metabolism and elimination of the chemical through the liver (liver clearance, *CL*, mg/min) were grouped into one process, represented as follows [\[38,](#page-12-23) [39,](#page-12-24) [40](#page-12-25)]:

$$
CL = Q_{liver_total} \times ER_{liver} \times C_{blood},
$$

where Q_{liver total is the total blood flow to liver (L/min), *ER*_{liver} the} extraction ratio of the chemical in the liver (no units), and *C*blood the concentration of the chemical in the blood (mg/L).

The abbreviations, definitions, values, units, and sources of physiological and pharmacokinetic parameters in the model are explained in [Tables 2](#page-6-0) and [3](#page-7-0). The model variables are shown in [Table 4.](#page-7-1)

MATLAB implementation

Following the definition of the mathematical model, we implemented it in software. We wrote an original code in MATLAB. The objective of this implementation was to simulate the model behavior with time. Within the code, we specified all the model parameters, the exposure scenario, and the model variables (see [Tables 2–](#page-6-0)[4\)](#page-7-1), as executable algorithms. The model variables to be integrated were represented as a system of 3 differential equations. We considered for example that the initial value of these variables (at time 0 of simulation) was 0 (random value; [Table 4](#page-7-1)). For integration, we used the ode23s solver in MATLAB as it can robustly integrate stiff systems of equations, i.e. those where the solution components may change slowly for an extended period of time. The model was created and simulated using MATLAB R2019b and MATLAB Online (basic) version.

Code conversion from MATLAB to the Systems Biology Markup Language (SBML)

For interoperability, we converted the MATLAB code to SBML, by using the 'Model ODE Converter for Creating Automated SBML Interoperability (MOCCASIN)' tool [\[41,](#page-12-26) [42\]](#page-12-27), version 1.3.0 [\[43\]](#page-12-28). This conversion was not straightforward and required adaptations on the MATLAB code, whereby we had to replace the function calls by the function formulas. Following this, MOCCASIN converted the MATLAB code to a preliminary SBML code. Then, we simulated the preliminary SBML code in COPASI (version 4.44) [[18](#page-12-5), [44\]](#page-12-29). For this, a few further changes were needed: (i) harmonization of the names of variables (y_1 was replaced by 'integrated_values_1', same for y_2 and y_3 ; (ii) replacing the conditions for dosing with an event; and (iii) manual introduction of the units for parameters and the simulation time. Finally the whole model was exported again to SBML.

Results

We start this section with a summary of recommendations aiming to ensure PBPK model reproducibility. As an illustration, we applied these recommendations during the development and implementation of the PBPK model code described in this

Table 2. Physiological parameter abbreviations, definitions, values, units, and sources in the proposed model example. The different values for adult men and women are shown. As an example, the values for men are used in the model

manuscript (see [Fig. 1\)](#page-4-0). The original model code is explained below.

General recommendations for documentation and implementation of physiologically-based pharmacokinetic models

The recommendations for PBPK model reporting and implementation are shown in [Tables 5](#page-8-0)[–7](#page-9-0) and in Supplementary Information (SI), [Tables S1](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data) and [S2](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data).

In the first place, we show the main model annotations (descriptive information) to be included both in the journal article and within the code [\(Table 5\)](#page-8-0). This includes notably a clear identification of: the model (name and version), authors (including ORCIDs), the sources for the model and code, and license.

In the second place, we summarize the information to describe the mathematical model in the journal article ([Table 6](#page-8-1)). Here, we refer in particular to the model purpose and applicability domain, structure, main assumptions, the model component values (with sources and units), and a set of quantitative results obtained by simulating the model.

Importantly, in [Table 7](#page-9-0), we provide recommendations for model implementation. For instance, we list the major executable elements within the code (numeric algorithms, solver, and numeric values of model components), important annotations, and others. The execution of the model code under specified simulation conditions must produce quantitative results, which should be published to facilitate reproducibility checks.

Furthermore, to make PBPK models more comprehensible, the naming and abbreviations of model components is important. In supplementary information (SI, section B), we provide general recommendations for parameter naming. Further, we show examples of abbreviations used in the literature for important processes and model components. For each process, we propose one or two abbreviations which seem the most clear and self-explanatory to us (SI, [Table S1\)](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data).

Finally, although not the focus of this work, other analyses for model evaluation, such as sensitivity analysis and model validation are mentioned in SI, [Table S2.](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data)

Writing an original, reproducible, and reusable PBPK model code in MATLAB and SBML formats

We have created an original PBPK model code in MATLAB and SBML formats. This code adheres to the recommendations for PBPK model reproducibility summarized in Results. The code and the numeric simulation results are available in Zenodo ([https://](https://doi.org/10.5281/zenodo.13838845) [doi.org/10.5281/zenodo.13838845\)](https://doi.org/10.5281/zenodo.13838845).

Briefly, the MATLAB code starts with the model annotations shown in SI, [Table S3](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data). Next, we include all the model parameters (abbreviations, values, units, definitions, sources) and the exposure scenarios, as defined within [Tables 2](#page-6-0) and [3.](#page-7-0) We specify the initial values of the model variables, as in [Table 4.](#page-7-1) This is followed by the definition of the model solver (ode23s function solver in MATLAB) and the system of differential equations [\(Table 4\)](#page-7-1). In the last part of the code, we show the literature references cited within the code.

When the code is executed in MATLAB, the model solver integrates the system of differential equations during the simulation time, starting from the initial values of the model variables, and

Abbreviation	Abbreviation in the code	Definition	Value	Units	Reference/s, source
ER _{liver}	ER liver	Extraction ratio of chemical in the liver, grouping metabolism and elimination processes (Emond et al., 2010)	0.70	Unitless	ER is a ratio and its value should be between 0 and 1, depending on the chemical. We select a random value, 0.7, which corresponds to a high clearance scenario in the animal model by MacLachlan [38]. Random values. We consider a hypothetical hydrophobic chemical that could globally have a higher accumulation in organs/tissues with higher total fat content (as a very simplistic example). The total fat content is higher in the whole body (average values of 21.3% of BW in men; 32.7% of BW in women) and in the liver (7% of liver wet weight), compared to the lipid content in blood (0.65%) [36, 37]. Therefore, for our hypothetical chemical, we propose random PC values in 'others' and in liver >1 Exposure scenario as in Upton et al. [32], including the dose, exposure time, and
PC_liver	PC liver	Partition coefficient of chemical between the liver and the blood	1.5	L/kg	
${\cal PC}_{_ \text{others}}$	PC others	Partition coefficient of chemical between 'others' (other tissues) and blood	3	L/kg	
Dose	Dose	Drug dose, administered intravenously	100	mg/min	
Time _{start_simul}	Time start simul	Starting time for the simulation	\circ	Min	differing in the exposure route (intravenous in our model)
Time _{end_simul}	Time end simul	Time at which the simulation ends	400	Min	
Time _{start_expos}	Time start expos	Time at which the chemical exposure begins	\circ	Min	
Time _{end_expos}	Time end expos	Time at which the chemical exposure ends	200	Min	

Table 3. Pharmacokinetic and exposure-related parameters: abbreviations, definitions, values, units, and sources in the proposed model example

Table 4. System of variables and differential equations in the MATLAB code created here, including the initial values for these variables

Where A is the amount of chemical in a given compartment (mg). C_{blood}, C_{liver,} and C_{others} are the concentrations of the chemical in the blood (mg/L), liver, and
other body tissues (mg/kg), respectively. V_{blood} is the chemical in other body tissues and the liver, respectively. Dose is the intravenous infusion of the drug (mg/min). ER_{liver} is the extraction ratio of the
chemical in the liver (unitless). The parameter values are sho ode23s solver in MATLAB.

taking into consideration all the parameter values and the chemical exposure scenario. The model simulates the time-dependent concentrations of the chemical in blood, liver, and *others*. By

execution of this code, the model simulation results are automatically provided both as a figure (SI, [Fig. S1,](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data) left panel) and in the form of an Excel Table, also available in Zenodo. This Table T[a](#page-8-2)ble 5. Recommended model^a annotations (descriptive information) and naming of model components to be included in the journal article^{[b](#page-8-3)} and within the [c](#page-8-4)ode^c. The underlined text denotes the additional proposals that we include in the current article for PBPK models, which may also be of interest for other systems biology models

^a Although the focus of the current paper is on PBPK models, most recommendations in this Table are applicable to systems biology models in general, as well as PBPK models. ^bThis refers to the peer-reviewed journal article or single reference description, where the mathematical model is described [\[10](#page-11-7)]. ^cSee definitions in [Table 1.](#page-2-0)

T[a](#page-8-2)[b](#page-8-2)le 6. Recommendations for mathematical model^a description in the journal article^b, the specific requirements for PBPK models are given in bold. The underlined text denotes the additional proposals that we include in the current article for PBPK models, which may also be of interest for other systems biology models.

aAlthough the focus of the current paper is on PBPK models, most recommendations in this Table are applicable to systems biology models in general, as well as PBPK models. Recommendations specific for PBPK models are shown with bold text. ^bThis refers to the peer-reviewed journal article or single reference description, where the mathematical model is described [\[10\]](#page-11-7). ^cSee definitions in [Table 1](#page-2-0).

T[a](#page-8-2)[b](#page-8-2)le 7. Model code^{a,b} content, structure and understandability, model implementation language, and dissemination. Specific requirements for PBPK models are in bold, and the underlined text denotes the additional proposals that we include in the current article for PBPK models, which may be of interest for other systems biology models too.

aAlthough the focus of the current paper is on PBPK models, most recommendations in this Table are applicable to Systems Biology models in general, as well as PBPK models. Recommendations specific for PBPK models are shown with bold text. bThe model code or 'computational model' is the implementation of the mathematical model in software [[9](#page-11-6), [10,](#page-11-7) [12](#page-11-9), [13\]](#page-11-10). cThis refers to the peer-reviewed journal article or single reference description, where the mathematical model is described [[10\]](#page-11-7).

is important since it gives other researchers the possibility to independently check the reproducibility of the model results.

The SBML code includes all the quantitative information (parameter values, equations, initial values, dose events) needed to simulate the model. To execute a SBML code, tools such as COPASI and JWS online may be used [[44\]](#page-12-29). When the SBML code is executed in COPASI, the simulation results (SI, [Fig. S1,](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data) right panel) are the same as with MATLAB (SI, [Fig. S1,](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data) left panel).

Discussion

Our work contributes to making PBPK models more reproducible and understandable. We reviewed the literature on proposed practices to increase the reproducibility of systems biology models in general and PBPK models in particular. Some published recommendations are globally applied in PBPK models, but some aspects from minimal information guidelines such as MIRIAM and particularly MIASE are not systematically applied in this field. These aspects include: model annotation, the description of the simulation conditions, the publication of numeric simulation results (to facilitate reproducibility assessment), the definition of license terms and the publication of the code. Reproducibility issues in many PBPK models include notably not sharing the code and not showing the full model equations [[30](#page-12-15), [31](#page-12-16)].

An important originality of our study is its applied perspective. Cronin *et al.* [\[49](#page-13-3)] discussed the conceptual application of FAIR principles (Findable, Accessible, Interoperable, Reusable) to *in silico* models for toxicology, including PBPK models. Tatka *et al.* [\[51](#page-13-6)] reviewed recommendations and relevant standards to increase the credibility of systems biology models for their context of use. We also review existing recommendations from the literature. Nevertheless, we focus on recommendations which help increase the reproducibility and comprehensibility of systems biology models and particularly of PBPK models. We illustrate these recommendations through the explanatory model code.

The recommendations summarized in [Tables 5](#page-8-0)[–7](#page-9-0) are meant to ensure a complete and clear description of the mathematical model in the publication and a consistent model implementation. For future PBPK models, these recommendations are directly applicable during model development, description and publication. For models which are already published, the recommendations in [Tables 5–](#page-8-0)[7](#page-9-0) can help detect potential missing / unclear or inconsistent information in those models, which should be then corrected by the model authors or by expert curators. Our recommendations could also be used as reproducibility criteria to select models for further development and reuse. We recommend reproducibility checks on published PBPK models start with a verification of the following aspects: (i) the mathematical equations for the model processes are shown and the abbreviations in the equations are brief ly defined (e.g. [Table 4](#page-7-1) with legend), and (ii) the model parameter values are shown with their units, sources, and abbreviations. Other reproducibility recommendations could be checked next.

We have created a clear and reproducible PBPK model and code, which is available in Zenodo. Many PBPK models in the literature do not have an associated model code available. We believe that our work helps understand the importance of sharing the model code for reproducibility. A key point to consider for model code publication is the existence of different license options. For example OpenAIRE, a major actor of the European Open Science Cloud, has recommended research work be licensed under CC BY 4.0 [\[47](#page-13-2), [48\]](#page-13-4). Under CC BY 4.0, the work can be reused by others, who must give appropriate credit to the creators and indicate if they (the users) have made changes to the original material [[52](#page-13-7)]. Original model code, such as the one we present here, is an important scientific result which requires expertise both on the type of model represented and on programming [\[53\]](#page-13-8). For these reasons, we decided to publish the PBPK model code under CC BY 4.0. Nevertheless, further exploration on license choices for future models would be beneficial.

As a limitation of our work developing an exemplar reproducible model code, we encoded the model in commercial software. We selected MATLAB for this based on its wide application in this field, its flexibility (which permitted us creating the code from scratch), human-readability, and our own experience with this software environment. In reality, our recommendations are independent of the software choice, since we focus on ensuring (i) the completeness and clarity of the model description and (ii) the consistency between the mathematical and computational model. So far, no standard format has been generalized in the PBPK modeling field. Further, many software options exist for PBPK model implementation [\[53\]](#page-13-8). In the PBPK model review database by Thompson *et al.* [\[30,](#page-12-15) [31\]](#page-12-16), up to 69 software tools were identified in the reviewed models. Of those, Simcyp, ACSL, and MATLAB were the three most common tools. Further, the results of an online survey to modelers in QSP confirmed the popularity of MATLAB, which was the preferred software tool among participants to that survey (*N* = 105) [\[54\]](#page-13-9). This may be in part explained by a wide application of these models for regulatory purposes and in commercial settings, where a recognized commercial platform like MATLAB may be preferred.

Recognizing the need to share models on a non-proprietary platform we have also created a standard version of the code, written in SBML. SBML is a standard format widely used in systems biology to facilitate model reuse and interoperability [\[6](#page-11-3), [14](#page-12-0), [18,](#page-12-5) [51](#page-13-6), [55](#page-13-10)]. This conversion was not straightforward and required some adaptations on the code (see Material and methods). On the one hand, this illustrates that there are constraints that can apply to a PBPK code in MATLAB if it is intended subsequently to share it more openly. On the other hand, MATLAB scripts are easy to annotate (as comments) and to understand, whereas SBML and other standard formats such as CellML [[51](#page-13-6)] are important for model interoperability and reuse, but not user-friendly when it comes to checking the code. As a direction for future research, further development of tools / methods to ease conversion to PBPK model code (such as the example we provide) from MATLAB and other software to SBML or other standard formats would be desirable.

For our example code we did not conduct sensitivity analysis, where the sensitivity of the model results to variations in parameter values is analyzed, or model validation, where model simulations are compared with experimental data not used at earlier stages of the model development. These verification steps are important for PBPK models developed to be applied in chemical risk assessment or for similar purposes. However, here the objective was to help improve the reproducibility of PBPK models. For this, we focused principally on the stages of model development and implementation, where the main reproducibility issues in biological models arise. We verified the biological plausibility of the

model, by carefully selecting physiological parameter values from the literature, and by ensuring that the body weight was the sum of the weights of all tissues and that the cardiac output was the sum of blood flows to all tissues. We conducted 'code verification' and 'calculation verification' (see [Table 1\)](#page-2-0), by ensuring the consistency between the mathematical model and the model code, and checking the quantitative simulation results. Hence, we confirm that the PBPK model developed here is mathematically correct and biologically plausible and the code allows simulation of the mathematical model.

Our code is open and flexible and facilitates potential modifications by the users for re-use. As a case study, we apply the model for an adult man. To simulate the model for a woman, the user can replace in the code the physiological parameter values for men by those for women, which we show in [Table 2](#page-6-0) and as comments within the code. Other examples of potential modifications on the code to represent different mathematical models are discussed in [SI](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data), section C. Following modifications on the code, particular attention would be needed to ensure that the mathematical model description and the model code are consistent, and to evaluate and validate the resulting model for its purpose.

Finally, the use of consistent and clear abbreviations for all the model components is crucial to increase the understandability of PBPK models. Whenever possible, controlled vocabularies and semantic annotations should be used [\[5](#page-11-12), [11](#page-11-8), [20\]](#page-12-6). However, to our knowledge, there are no such resources for many PBPK model components (e.g. parameters). In this context, it is essential to define all the abbreviations and use them consistently in the article and within the code. As a first step towards harmonization, we propose a list of abbreviations for PBPK models (SI, [Table S1](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data)). We have prioritized examples of abbreviations that are frequently used in this field. In general, self-explanatory abbreviations are more understandable and would also be preferred. For the same reason, as subscripts to specify the tissues / organs (where needed), we recommend using their full names. We have selected abbreviations for several major PBPK model components, but this list is not exhaustive and does not consider all processes which can be represented in PBPK models. As a future development, it would be valuable to create a dynamic list where new abbreviations for other model components and processes are added, the proposed abbreviations discussed with the broad community of model developers and users, and harmonized. In the end, a standardized list would permit that new PBPK models apply the same abbreviations for the same processes, which would be an important progress towards ensuring PBPK model comprehensibility and reuse.

Conclusion

In summary, we believe our work helps towards convergence of reproducibility practices in the PBPK modeling and other systems biology fields, from an applied perspective. We illustrate how to apply the recommendations step by step, from the creation of a conceptual mathematical model to the model implementation and publication. Further, by converting the code from MATLAB to SBML, our work can be easily visualized by modelers in other systems biology fields too.

One aspect which warrants further investigation is the practical application of standards to PBPK models. Standards are developed by the systems biology community, coordinated by the Computational Modeling in Biology Network (COMBINE), to facilitate model interoperability, reusability and integration [[4,](#page-11-11) [6,](#page-11-3)

[8,](#page-11-5) [56](#page-13-11)]. Here, we emphasize the use of standards where they exist. As an example, we have converted the explanatory MATLAB code to SBML, by using MOCCASIN. This conversion was not straightforward and some manual adaptations on the code were needed. Therefore, we recommend developing more conversion tools to allow an automatic conversion of PBPK codes from different software environments to SBML. Other examples of standards are COMBINE archives and the Simulation Experiment Description Markup Language (SED-ML) [\[4\]](#page-11-11). COMBINE Archives allow to organize in a single 'container' all the model files available in standard formats [[44](#page-12-29), [56](#page-13-11)]. SED-ML permits to create machine-readable descriptions of the simulation conditions and their results [[57\]](#page-13-12).

In our work, the model files are identified ([Table S3\)](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data) and available (see Data availability statement). We describe the simulation conditions in [Tables 2–](#page-6-0)[4](#page-7-1) and the numeric simulation results are also provided. The applicability and added value of standards such as COMBINE Archives and SED-ML for PBPK models should be explored. As explained by König *et al.* [\[5\]](#page-11-12), the suitability and potential adaptations of standards for specific systems biology fields should be analyzed and determined through cross-domain collaborations.

To conclude, this work is the result of a multidisciplinary collaboration between modelers and researchers in PBPK modeling and in other systems biology fields, with a major involvement of the ELIXIR Systems Biology Community. More multidisciplinary collaborations should promote further harmonization of good modeling practices in both fields.

Key Points

- We review and summarize literature recommendations aiming to ensure the reproducibility of PBPK and systems biology models.
- We illustrate our recommendations by creating and publishing an example of reproducible and understandable PBPK model code in MATLAB, which we have converted to SBML.
- We propose a list of self-explanatory abbreviations for PBPK model components, as a first step towards a dynamic list of harmonized abbreviations.
- Our work helps increase the reproducibility of PBPK models, make them more comprehensible, and harmonize good modeling practices in systems biology.

Supplementary data

[Supplementary data](https://academic.oup.com/bib/article-lookup/doi/10.1093/bib/bbae569#supplementary-data) is available at *Briefings in Bioinformatics* online.

Conflict of interest: None declared.

Funding

This project was supported by Maastricht University and the ELIXIR Systems Biology Community by way of the SYBEL Implementation Study. E.D.R.'s time on this work was supported by the VHP4Safety project. The VHP4safety project is funded by the Netherlands Research Council, NWO 'Netherlands Research Agenda: Research on Routes by Consortia'—NWA-ORC 1292.19.272. E.D.R. and M.S. time on this work was supported by the European Union's Horizon 2020 research and innovation program under grant agreement no. 733032, HBM4EU. E.D.R., S.M., and M.S. were also supported by the Czech Ministry of Education, Youth and Sports (ESFRI RECETOX RI LM2023069 and ESFRI ELIXIR LM2023055) and the European Union's Horizon 2020 Research and Innovation Programme under grant agreement no. 857560 (CETOCOEN Excellence). This publication ref lects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains.

Data availability

The original PBPK model code in MATLAB and SBML formats, and the numeric simulation results in MATLAB are available in ZENODO, under CC BY 4.0 license ([https://doi.org/10.5281/](https://doi.org/10.5281/zenodo.13838845) [zenodo.13838845](https://doi.org/10.5281/zenodo.13838845); the current manuscript should be cited).

References

- [1.](#page-1-23) Kitano H. Systems biology: a brief overview. *Science* 2002;**295**: 1662–4. <https://doi.org/10.1126/science.1069492>
- [2.](#page-1-24) Meyer P, Saez-Rodriguez J. Advances in systems biology modeling: 10 years of crowdsourcing DREAM challenges. *Cell Syst* 2021;**12**:636–53. [https://doi.org/10.1016/j.cels.2021.05.015.](https://doi.org/10.1016/j.cels.2021.05.015)
- [3.](#page-1-25) Martins Dos Santos V, Anton M, Szomolay B. *et al.* Systems biology in ELIXIR: modelling in the spotlight. *F1000Res* 2022;**11**:1265. <https://doi.org/10.12688/f1000research.126734.2>.
- [4.](#page-2-1) Niarakis A, Waltemath D, Glazier J. *et al.* Addressing barriers in comprehensiveness, accessibility, reusability, interoperability and reproducibility of computational models in systems biology. *Brief Bioinform* 2022;**23**:bbac212. [https://doi.org/10.1093/bib/](https://doi.org/10.1093/bib/bbac212) [bbac212.](https://doi.org/10.1093/bib/bbac212)
- [5.](#page-1-26) König M, Oellrich A, Waltemath D. *et al.* Challenges and opportunities for system biology standards and tools in medical research. *Proceedings of the 7th Workshop on Ontologies and Data in Life Sciences (ODLS)*, organized by the GI Workgroup Ontologies in Biomedicine and Life Sciences (OBML). Halle (Saale), Germany, September 29–30, 2016. CEUR Workshop Proceedings, Vol. **1692**, C.1–6 [\(https://ceur-ws.org/Vol-1692/](https://ceur-ws.org/Vol-1692/)).
- [6.](#page-1-26) Waltemath D, Wolkenhauer O. How Modeling standards, software, and initiatives support reproducibility in systems biology and systems medicine. *IEEE Transactions on Biomedical Engineering* 2016;**63**:1999–2006. [https://doi.org/10.1109/tbme.2016.2555481.](https://doi.org/10.1109/tbme.2016.2555481)
- [7.](#page-1-27) Kirouac DC. Open models for clinical pharmacology. *Clin Pharmacol Ther* 2020;**107**:700–2. <https://doi.org/10.1002/cpt.1738>.
- [8.](#page-1-28) Voit EO, Shah AM, Olivença DV. *et al.* What's next for computational systems biology? *Frontiers in Systems Biology* 2023;**3**. [https://doi.org/10.3389/fsysb.2023.1250228.](https://doi.org/10.3389/fsysb.2023.1250228)
- [9.](#page-1-29) OECD. Guidance document on the characterisation, validation and reporting of physiologically based kinetic (PBK) models for regulatory purposes. In: *OECD Series on Testing and Assessment, No. 331*, p. 101. Environment, Health and Safety, Environment Directorate, OECD, 2021.
- [10.](#page-2-2) Le Novere N, Finney A, Hucka M. *et al.* Minimum information requested in the annotation of biochemical models (MIRIAM). *Nat Biotechnol* 2005;**23**:1509–15. <https://doi.org/10.1038/nbt1156>.
- [11.](#page-2-3) Neal ML, König M, Nickerson D. *et al.* Harmonizing semantic annotations for computational models in biology. *Brief Bioinform* 2019;**20**:540–50. <https://doi.org/10.1093/bib/bby087>.
- [12.](#page-2-4) ASME. *Assessing Credibility of Computational Modeling through Verification and Validation: Application to Medical Devices, V 40–2018*. ASME, Two Park Avenue New York, NY, 2018.
- [13.](#page-2-5) FDA. Assessing the credibility of computational Modeling and simulation in medical device submissions. In:*Guidance for Industry and Food and Drug Administration Staff. Document Issued on November 17, 2023*, p. 42. U.S. Docket Number: FDA-2021-D-0980. Department of Health and Human Services. Food and

Drug Administration Center for Devices and Radiological Health (CDRH). CDRH Office of Policy, Silver Spring, MD, 2023.

- [14.](#page-2-6) Malik-Sheriff RS, Glont M, Nguyen TVN. *et al.* BioModels-15 years of sharing computational models in life science. *Nucleic Acids Res* 2020;**48**:D407–15. <https://doi.org/10.1093/nar/gkz1055>.
- [15.](#page-2-7) Wilkinson MD, Dumontier M, Aalbersberg IJ. *et al.* The FAIR guiding principles for scientific data management and stewardship. *Sci Data* 2016;**3**:160018. [https://doi.org/10.1038/sdata.2016.18.](https://doi.org/10.1038/sdata.2016.18)
- [16.](#page-2-8) Jacobsen A, de Miranda Azevedo R, Juty N. *et al.* FAIR principles: interpretations and implementation considerations. *Data Intelligence* 2020;**2**:10–29. [https://doi.org/10.1162/dint_r_00024.](https://doi.org/10.1162/dint_r_00024)
- [17.](#page-2-9) Porubsky V, Smith L, Sauro HM. Publishing reproducible dynamic kinetic models. *Brief Bioinform* 2021;**22**. [https://doi.](https://doi.org/10.1093/bib/bbaa152) [org/10.1093/bib/bbaa152.](https://doi.org/10.1093/bib/bbaa152)
- [18.](#page-2-10) Tiwari K, Kananathan S, Roberts MG. *et al.* Reproducibility in systems biology modelling. *Mol Syst Biol* 2021;**17**:e9982. [https://](https://doi.org/10.15252/msb.20209982) [doi.org/10.15252/msb.20209982.](https://doi.org/10.15252/msb.20209982)
- [19.](#page-2-11) Plesser HE. Reproducibility vs. replicability: a brief history of a confused terminology. *Front Neuroinform* 2017;**11**:76. [https://doi.](https://doi.org/10.3389/fninf.2017.00076) [org/10.3389/fninf.2017.00076](https://doi.org/10.3389/fninf.2017.00076).
- [20.](#page-2-12) Waltemath D, Adams R, Beard DA. *et al.* Minimum information about a simulation experiment (MIASE). *PLoS Comput Biol* 2011;**7**:e1001122. <https://doi.org/10.1371/journal.pcbi.1001122>.
- [21.](#page-2-13) Mathworks. *Choose an ODE Solver*. The MathWorks, Inc., 2024. [https://nl.mathworks.com/help/matlab/math/choose-an-ode](https://nl.mathworks.com/help/matlab/math/choose-an-ode-solver.html)[solver.html](https://nl.mathworks.com/help/matlab/math/choose-an-ode-solver.html) (accessed June 29, 2024).
- [22.](#page-2-14) Andersen ME, Clewell HJ, Frederick CB. Applying simulation modeling to problems in toxicology and risk assessment: a short perspective. *Toxicol Appl Pharmacol* 1995;**133**:181–7. [https://doi.](https://doi.org/10.1006/taap.1995.1140) [org/10.1006/taap.1995.1140](https://doi.org/10.1006/taap.1995.1140).
- [23.](#page-2-15) Goodman SN, Fanelli D, Ioannidis JP. What does research reproducibility mean? *Sci Transl Med* 2016;**8**:341ps312. [https://doi.](https://doi.org/10.1126/scitranslmed.aaf5027) [org/10.1126/scitranslmed.aaf5027.](https://doi.org/10.1126/scitranslmed.aaf5027)
- [24.](#page-2-16) Andersen ME. Development of physiologically-based pharmacokinetic and physiologically-based pharmacodynamic models for applications in toxicology and risk assessment. *Toxicol Lett* 1995;**79**:35–44. [https://doi.org/10.1016/0378-4274\(95\)03355-o](https://doi.org/10.1016/0378-4274(95)03355-o).
- [25.](#page-2-17) Adler S, Basketter D, Creton S. *et al.* Alternative (nonanimal) methods for cosmetics testing: current status and future prospects-2010. *Arch Toxicol* 2011;**85**:367–485. [https://doi.](https://doi.org/10.1007/s00204-011-0693-2) [org/10.1007/s00204-011-0693-2.](https://doi.org/10.1007/s00204-011-0693-2)
- 26. Hirasawa K, Abe J, Nagahori H. *et al.* Novel approach for verification of a human PBPK modeling strategy using chimeric mice in the health risk assessment of epyrifenacil. *Toxicol Appl Pharmacol* 2023;**465**:116439. <https://doi.org/10.1016/j.taap.2023.116439>.
- [27.](#page-2-17) Lin Z, Basili D, Chou WC. Preface to the special issue of food and chemical toxicology on "new approach methodologies and machine learning in food safety and chemical risk assessment: development of reproducible, open-source, and user-friendly tools for exposure, toxicokinetic, and toxicity assessments in the 21st century". *Food Chem Toxicol* 2024;**190**:114809. [https://doi.](https://doi.org/10.1016/j.fct.2024.114809) [org/10.1016/j.fct.2024.114809.](https://doi.org/10.1016/j.fct.2024.114809)
- [28.](#page-3-0) Loizou G, Spendiff M, Barton HA. *et al.* Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. *Regul Toxicol Pharmacol* 2008;**50**:400–11. [https://doi.org/10.](https://doi.org/10.1016/j.yrtph.2008.01.011) 1016/j.yrtph.2008.01.011.
- [29.](#page-3-1) EFSA. Scientific opinion on good modelling practice in the context of mechanistic effect models for risk assessment of plant protection products. PPR panel (EFSA panel on plant protection products and their residues). *EFSA J* 2014;**12**:92. [https://doi.](https://doi.org/10.2903/j.efsa.2014.3589) [org/10.2903/j.efsa.2014.3589.](https://doi.org/10.2903/j.efsa.2014.3589)
- [30.](#page-3-2) Thompson CV, Firman JW, Goldsmith MR. *et al.* A systematic review of published physiologically-based kinetic models and an assessment of their chemical space coverage. *Altern Lab Anim* 2021;**49**:197–208. [https://doi.org/10.1177/02611929211060264.](https://doi.org/10.1177/02611929211060264)
- [31.](#page-3-3) EC JRC. *A Systematic Review of Published Physiologically-Based Kinetic Models and an Assessment of their Chemical Space Coverage*. European Commission, Joint Research Centre (JRC), 2021. [Dataset] PID: [http://data.europa.eu/89h/f98e9abf-8435-4578](http://data.europa.eu/89h/f98e9abf-8435-4578-acd6-3c35b5d1e50c) [acd6-3c35b5d1e50c](http://data.europa.eu/89h/f98e9abf-8435-4578-acd6-3c35b5d1e50c).
- [32.](#page-4-1) Upton RN, Foster DJR, Abuhelwa AY. An introduction to physiologically-based pharmacokinetic models. *Pediatr Anesth* 2016;**26**:1036–46. <https://doi.org/10.1111/pan.12995>.
- [33.](#page-4-2) EMA. *Guideline on the Reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation*. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), 13 December 2018. EMA, London, UK, 2018. EMA/CHMP/ 458101/2016.
- [34.](#page-4-3) Teeguarden JG, Waechter JM, Clewell HJ. *et al.* Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: a physiologically based pharmacokinetic approach. *Toxicol Sci* 2005;**85**: 823–38. [https://doi.org/10.1093/toxsci/kfi135.](https://doi.org/10.1093/toxsci/kfi135)
- [35.](#page-4-4) Loccisano AE, Campbell JL, Andersen ME. *et al.* Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. *Regul Toxicol Pharmacol* 2011;**59**: 157–75. [https://doi.org/10.1016/j.yrtph.2010.12.004.](https://doi.org/10.1016/j.yrtph.2010.12.004)
- [36.](#page-4-5) ICRP. *Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values*. Stockholm, Sweden: The International Commission on Radiological Protection (ICRP)Publication 89, 2002, 442. ISSN 0146-6453.
- [37.](#page-4-6) Brown RP, Delp MD, Lindstedt SL. *et al.* Physiological parameter values for physiologically based pharmacokinetic models. *Toxicol Ind Health* 1997;**13**:407–84. [https://doi.org/10.](https://doi.org/10.1177/074823379701300401) 1177/074823379701300401.
- [38.](#page-5-1) MacLachlan DJ. Influence of physiological status on residues of lipophilic xenobiotics in livestock. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess* 2009;**26**:692–712. [https://doi.](https://doi.org/10.1080/02652030802669170) [org/10.1080/02652030802669170](https://doi.org/10.1080/02652030802669170).
- [39.](#page-5-2) Domínguez-Romero E. *Modelling the Hexabromocyclododecane (HBCD) Transfer Kinetics in the Laying Hen: Impact of the Physiological Features (in French: Modélisation du Devenir de l'hexabromocyclododécane (HBCD) Chez la Poule Pondeuse : Influence Des caractéristiques Physiologiques)* PhD thesis. Vandœuvre-lès-Nancy, France: University of Lorraine. Doctoral School RP2E (Ressources, Procédés, Environnement), 2016. 307 [https://hal.](https://hal.univ-lorraine.fr/tel-01752364/document) [univ-lorraine.fr/tel-01752364/document](https://hal.univ-lorraine.fr/tel-01752364/document).
- [40.](#page-5-3) Emond C, Raymer JH, Studabaker WB. *et al.* A physiologically based pharmacokinetic model for developmental exposure to BDE-47 in rats. *Toxicol Appl Pharmacol* 2010;**242**:290–8. [https://doi.](https://doi.org/10.1016/j.taap.2009.10.019) [org/10.1016/j.taap.2009.10.019](https://doi.org/10.1016/j.taap.2009.10.019).
- [41.](#page-5-4) SBML. *Systems Biology Markup Language (SBML) Software and Models*. 2023. <http://sbml.org/software/> (accessed April 18, 2023; link updated on Oct. 29, 2024).
- [42.](#page-5-5) Gómez HF, Hucka M, Keating SM. *et al.* MOCCASIN: converting MATLAB ODE models to SBML. *Bioinformatics* 2016;**32**:1905–6. [https://doi.org/10.1093/bioinformatics/btw056.](https://doi.org/10.1093/bioinformatics/btw056)
- [43.](#page-5-6) SBML. *SBMLteam/MOCCASIN*, GitHub, 2024. [https://github.com/](https://github.com/sbmlteam/moccasin?tab=readme-ov-file) [sbmlteam/moccasin?tab=readme-ov-file](https://github.com/sbmlteam/moccasin?tab=readme-ov-file) (accessed April 3, 2024).
- [44.](#page-5-7) Stanford NJ, Scharm M, Dobson PD. *et al.* Data management in computational systems biology: exploring standards, tools, databases, and packaging best practices. *Methods*

Mol Biol 2019;**2049**:285–314. [https://doi.org/10.1007/978-1-4939-](https://doi.org/10.1007/978-1-4939-9736-7_17) 9736-7_17.

- [45.](#page-6-1) Kenner T. The measurement of blood density and its meaning. *Basic Res Cardiol* 1989;**84**:111–24. [https://doi.org/10.1007/](https://doi.org/10.1007/BF01907921) [BF01907921.](https://doi.org/10.1007/BF01907921)
- [46.](#page-6-2) Vitello DJ, Ripper RM, Fettiplace MR. *et al.* Blood density is nearly equal to water density: a validation study of the gravimetric method of measuring intraoperative blood loss. *J Vet Med* 2015;**2015**:1–4. 152730. <https://doi.org/10.1155/2015/152730>.
- [47.](#page-8-5) OpenAIRE. *Guides for Researchers. How Do I License my Research Data?* 2024. [https://www.openaire.eu/how-do-i-license-my](https://www.openaire.eu/how-do-i-license-my-research-data)[research-data](https://www.openaire.eu/how-do-i-license-my-research-data) (accessed March 29, 2024).
- [48.](#page-8-6) Margoni T, Tsiavos P. *D3.2—Toolkit for Researchers on Legal Issues* Version 1.0—Final. Public. Zenodo: OpenAIRE | ADVANCE, 2018. 42 <10.5281/zenodo.2574619>.
- [49.](#page-8-5) Cronin MTD, Belfield SJ, Briggs KA. *et al.* Making in silico predictive models for toxicology FAIR. *Regul Toxicol Pharmacol* 2023;**140**:105385. <https://doi.org/10.1016/j.yrtph.2023.105385>.
- [50.](#page-8-7) Najjar A, Punt A, Wambaugh J. *et al.* Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment. *Arch Toxicol* 2022;**96**:3407–19. [https://](https://doi.org/10.1007/s00204-022-03356-5) [doi.org/10.1007/s00204-022-03356-5.](https://doi.org/10.1007/s00204-022-03356-5)
- [51.](#page-9-1) Tatka LT, Smith LP, Hellerstein JL. *et al.* Adapting modeling and simulation credibility standards to computational sys-

tems biology. *J Transl Med* 2023;**21**:501. [https://doi.org/10.1186/](https://doi.org/10.1186/s12967-023-04290-5) [s12967-023-04290-5](https://doi.org/10.1186/s12967-023-04290-5).

- [52.](#page-10-0) CC. *Creative Commons (CC): CC By 4.0 Deed, Attribution 4.0 International*. Creative Commons, CA, 2024. [https://creativecommons.](https://creativecommons.org/licenses/by/4.0/) [org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/) (accessed April 8, 2024).
- [53.](#page-10-1) Hack CE, Efremenko AY, Pendse SN. *et al.* Chapter 4 physiologically based pharmacokinetic modeling software. In: Fisher JW, Gearhart JM, Lin Z (eds.), *Physiologically Based Pharmacokinetic (PBPK) Modeling*, pp. 81–126. Academic Press, 2020.
- [54.](#page-10-2) Ermakov S, Schmidt BJ, Musante CJ. *et al.* A survey of software tool utilization and capabilities for quantitative systems pharmacology: what we have and what we need. *CPT Pharmacometrics Syst Pharmacol* 2019;**8**:62–76. [https://doi.org/10.1002/psp4.12373.](https://doi.org/10.1002/psp4.12373)
- [55.](#page-10-3) Domínguez-Romero E, Anton M, Çınar O. *et al. Specialised Workshop on Physiologically-Based Pharmacokinetic (PBPK) Modelling: Tools Organisation, Parameter Estimation Resources and Model Deposition and Standards Related to Model Interoperability. Elixir Systems Biology Implementation Study* WP 2, Use cases. M2.3 Report (July 25, 2023). 2023.
- [56.](#page-11-13) Scharm M, Waltemath D. A fully featured COMBINE archive of a simulation study on syncytial mitotic cycles in. *F1000Res* 2016;**5**:2421. [https://doi.org/10.12688/f1000research.9379.1.](https://doi.org/10.12688/f1000research.9379.1)
- [57.](#page-11-14) Smith L, Bergmann FT, Garny A. *et al. Simulation Experiment Description Markup Language (SED-ML): Level 1 Version 4. September 28, 2021*. 2021, p. 133. [https://sed-ml.org.](https://sed-ml.org)